84.66
Haemonetics Corp. stock is currently priced at $84.66, with a 24-hour trading volume of 338.62K.
It has seen a -1.62% decreased in the last 24 hours and a -13.05% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $85.50 pivot point. If it approaches the $84.64 support level, significant changes may occur.
Previous Close:
$86.05
Open:
$85.44
24h Volume:
338.62K
Market Cap:
$4.31B
Revenue:
$1.27B
Net Income/Loss:
$126.57M
P/E Ratio:
34.00
EPS:
2.49
Net Cash Flow:
$128.75M
1W Performance:
-1.11%
1M Performance:
-13.05%
6M Performance:
-4.62%
1Y Performance:
+0.02%
Haemonetics Corp. Stock (HAE) Company Profile
Name
Haemonetics Corp.
Sector
Industry
Phone
781-848-7100
Address
400 Wood Road, Braintree, MA
Haemonetics Corp. Stock (HAE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-13-22 | Initiated | Mizuho | Buy |
Jan-27-22 | Downgrade | Needham | Buy → Hold |
Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
Aug-17-21 | Resumed | Raymond James | Outperform |
Jun-17-21 | Initiated | Citigroup | Buy |
May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
Jan-10-20 | Initiated | Needham | Buy |
Aug-07-19 | Reiterated | Barrington Research | Outperform |
May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-08-19 | Reiterated | Barrington Research | Outperform |
Aug-09-18 | Reiterated | Barrington Research | Outperform |
Feb-07-18 | Reiterated | Barrington Research | Outperform |
Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-08-17 | Reiterated | Barrington Research | Outperform |
Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Nov-07-16 | Reiterated | The Benchmark Company | Hold |
Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
Aug-02-16 | Reiterated | Jefferies | Buy |
Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp. Stock (HAE) Latest News
HAE vs. BSX: Which Stock Should Value Investors Buy Now?
Zacks Investment Research
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance UK
Yahoo Finance UK
Zacks.com featured highlights include Skechers, Walmart, Haemonetics, AZZ and BOK Financial - Yahoo Finance
Yahoo Finance
Haemonetics Co. (NYSE:HAE) Stock Holdings Trimmed by Parkman Healthcare Partners LLC - MarketBeat
MarketBeat
Taking a look at what insiders are doing to gauge the Haemonetics Corp. (HAE)'s direction – Knox Daily - Knox Daily
Knox Daily
Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation
Zacks Investment Research
Haemonetics Corp. Stock (HAE) Financials Data
Haemonetics Corp. (HAE) Revenue 2024
HAE reported a revenue (TTM) of $1.27 billion for the quarter ending December 31, 2023, a +12.48% rise year-over-year.
Haemonetics Corp. (HAE) Net Income 2024
HAE net income (TTM) was $126.57 million for the quarter ending December 31, 2023, a +32.18% increase year-over-year.
Haemonetics Corp. (HAE) Cash Flow 2024
HAE recorded a free cash flow (TTM) of $128.75 million for the quarter ending December 31, 2023, a +0.50% increase year-over-year.
Haemonetics Corp. (HAE) Earnings per Share 2024
HAE earnings per share (TTM) was $2.46 for the quarter ending December 31, 2023, a +32.97% growth year-over-year.
About Haemonetics Corp.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Cap:
|
Volume (24h):